Dynavax Technologies Co. (NASDAQ:DVAX) Holdings Decreased by Invesco Ltd.

Invesco Ltd. trimmed its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,649,585 shares of the biopharmaceutical company's stock after selling 58,864 shares during the quarter. Invesco Ltd. owned about 1.25% of Dynavax Technologies worth $21,065,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Russell Investments Group Ltd. boosted its position in shares of Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 2,034 shares during the period. GAMMA Investing LLC lifted its position in Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Dynavax Technologies in the 4th quarter valued at approximately $71,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 1,076 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group reduced their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock traded up $0.01 during trading on Wednesday, hitting $10.73. The stock had a trading volume of 1,564,292 shares, compared to its average volume of 2,187,988. The business has a fifty day moving average of $12.90 and a two-hundred day moving average of $12.56. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The firm has a market cap of $1.33 billion, a P/E ratio of 59.62 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.